68 related articles for article (PubMed ID: 3230273)
1. Searching for the face of neoplasia.
Boland CR
J Clin Gastroenterol; 1988 Dec; 10(6):599-604. PubMed ID: 3230273
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
3. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH
Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
7. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
8. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
9. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
10. 'Senescence-associated' beta-galactosidase activity in the upper gastrointestinal tract.
Going JJ; Stuart RC; Downie M; Fletcher-Monaghan AJ; Keith WN
J Pathol; 2002 Apr; 196(4):394-400. PubMed ID: 11920734
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
13. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
14. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
16. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
[TBL] [Abstract][Full Text] [Related]
17. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
18. [Risk estimation in Barrett's esophagus: biomolecular marker and histopathologic classification].
Walch A; Schmitt-Gräff A; Stein H; Werner M
Zentralbl Chir; 2002 Dec; 127(12):1073-7. PubMed ID: 12529823
[TBL] [Abstract][Full Text] [Related]
19. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
Fléjou JF
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
[TBL] [Abstract][Full Text] [Related]
20. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]